Connect Biopharma Holdings (CNTB)
(Delayed Data from NSDQ)
$1.57 USD
-0.04 (-2.48%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.57 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CNTB 1.57 -0.04(-2.48%)
Will CNTB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CNTB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CNTB
What Makes Connect Biopharma Holdings Limited Sponsored ADR (CNTB) a Strong Momentum Stock: Buy Now?
CNTB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CNTB
CNTB falls 2.48% on September 19, leaving the technical picture intact
Is CNTB about to break its pattern? NR7 shows up after a flat session
Stochastic Buy Signal appears for CNTB after 0.0% move
CNTB's price rises by 0.63% on September 16, though its technical setup remains stable.
Connect Biopharma Executives Increase Share Holdings